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Estrogen Receptors and Breast Cancer
by R. 1. Nicholson,* K. Griffiths,* R. W. Blamey,t H. M.
Bishop,t and J. L. Haybittle*
Estrogen receptors have been assayed in a series of primary breast cancers from postmenopausal
women; 59%o of which were estrogen-receptor positive. These patients survived for a significantly
longer period of time than those whose tumors were estrogen-receptor negative. The effect of
estrogen-receptor status was only seen (and then markedly accentuated) in patients who had
lymph-node invasion at the time ofmastectomy. Such determinations also appear to be ofvalue
in preselecting those patients who, on recurrence, will benefit from tamoxifen therapy.
Introduction
One of the most striking features about breast
cancer is that there appears to be at least two
distinct practical categories of the disease. There
are those tumors which are hormone-responsive
and which will regress following the removal of, or
interference with, their hormonal environment;
objective breast tumor regressions often with ex-
tensive remission intervals are observed in
approximately 30% of patients following the surgi-
cal removal of their ovaries, adrenal glands, or
pituitary gland, or after the addition of pharmaco-
logical amounts ofhormones orantiestrogens; there
are other tumors whose growth appears to be
independent of any substantial hormonal associa-
tion and which derive little measurable benefit from
these endocrinetreatments. Although littleis known
about how these types of disease arise from the
normal epithelium of the breast and indeed, what
agents both endogenous and environmental, act to
initiate and regulate their development, growth
and interrelationships with one another, neverthe-
less it is apparent that they do represent extreme
biological variants, and anecdotal evidence sug-
gests that they are reflected in other fundamental
and highly variable characteristics of the tumor,
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such as theirdegree ofdifferentiation, theirgrowth
rates, and possibly even their invasiveness.
Currently, the most widely and successfully used
method for the determination of the hormone
responsiveness of breast tumors is the measure-
ment ofthe intracellular concentration ofa protein
referred to as the estrogen receptor (1). This
protein is present in the cytoplasm of hormone-
responsive tumor cells and binds incoming estradiol
with selective high affinity. The binding of the
hormone to the receptor (ER) is then thought to
facilitate the transfer to and retention of the
receptor complex within the nucleus and thereby
increase transcription of the DNA template, a
process essential for cell maintenance and division.
Clinical studies indicate that while the presence of
ERs in secondary recurrent breast cancer is
associated with a 50-60% objective breast tumor
response rate to endocrine measures, in their
absence only 5-10% of patients respond to these
treatments (2). Such data have led to the routine
use of ER measurements in breast cancer speci-
mens in preselecting patients most likely to derive
benefit from these endocrine therapies.
Furthermore, it has recently become evident
that womenwhose primarytumors are ER-positive
have a significantly longer disease-free interval, in
the absence of any systemic therapy, than those
who have ER-negative tumors, and that when ER
status is combined with the lymph-node staging of
the disease, both parameters act together to pro-
vide an accurate means by which early recurrence
maybe predicted (3, 4). The presentreport extends
143these initial observations to examine the value of
such ER measurements in relation to the survival
ofthe patient. In addition, ER analysis on primary
breast tumor specimens has been examined with
respect to the response ofthe secondary disease to
endocrine therapy.
Materials and Methods
Patients
Between 1973 and 1977, 250 women, aged be-
tween 27 and 75 years, with primary operable
breast cancer, who consecutively presented to one
surgeon (RWB), underwent a simple mastectomy
and triple lymph-node biopsy (5). Ofthese women,
148 were postmenopausal and ER status was mea-
sured on 133 of these. All patients have been
followed up for at least 2 years.
At mastectomy, lymph node biopsies were re-
moved from the lower axilla, from the apex of the
axilla and from the internal mammary tumor chain
at the second intercostal space. Patients with no
tumor histologically evident in any node were
classified as Stage A; those with tumor only in
nodes from the low axillawere classified as Stage B
and patients with tumorinlymph nodes at the apex
ofthe axilla or in the second intercostal space were
designated Stage C. Patients were followed up at a
postmastectomy clinic at 3-month intervals to 18
months and thereafter at 6-monthly intervals and
have not been subjected to any form of adjuvant
therapy.
Survival curves were derived from life-table
analyses of the data at each follow-up time. Com-
parison between the curves were made with tech-
niques described by Haybittle and Freeman (6)-an
approach which evaluates differences between the
whole curves rather than individual points on the
curve.
For this study recurrence was defined as the
development of symptomatic distant metastases
confirmed by x-ray, abnormal liver function tests,
or brain action. Once symptomatic recurrence was
diagnosed, the first line of endocrine treatment in
premenopausal women was oophorectomy and in
postmenopausal patients tamoxifen therapy (10 mg
b.d.). In addition, radiotherapy was given to par-
ticular sites (e.g. vertebral metastases) when indi-
cated. Patients who failed to show objective response
to endocrine treatment when assessed six months
afterinitiation oftherapy were treated with combi-
nation chemotherapy, as were patients showing
obvious tumor progression two months after the
initiation ofendocrinetherapy. Patientswhoshowed
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objective response aftersix months endocrine ther-
apy received secondary endocrine therapy in the
form of adrenalectomy, once the response had
ended.
Estrogen Receptors
At operation a representative portion of the
primary tumor was frozen in liquid nitrogen and
stored at-70°C before beingtransported in Dry Ice
to the Tenovus Institute for subsequent ER assay.
Details ofthe assay have been previously reported
(3). Tumors were considered positive only when
they contained more than 5 fmole specific estradiol
binding/mg cytosol protein.
Results
ER Status and Survival
Of the 133 postmenopausal women, 79 (59%)
were ER positive and 54 (41%) ER negative. To
date 39 have died. Figure 1 shows the survival
curve for patients with ER-positive tumors against
that for patients with ER-negative tumors. Pa-
tients with ER-positive tumors survive longerthan
those with ER-negative tumors (p < 0.025). Fur-
thermore, it was observed that there was no
additional advantage for those patients whose pri-
mary tumor contained receptor levels in excess of
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FIGURE 1. ER status and survival. Percentage survival of133
postmenopausal women undergoing simple mastectomy: (0)
ER +;(0)ER-. Numbersaboveabscissaindicatenumbersof
women remaining in the study at each follow-up point.
Environmental Health Perspectiveswere premenopausal and underwent oophorectomy
and37werepostmenopausal andreceivedtamoxifen
(Nolvadex, ICI 46474). The overall response rates
to oophorectomy and tamoxifen were 30 and 32%,
respectively. Eleven out of20 premenopausal women
were ER-positive and ofthose4(36%) responded to
\h;, oophorectomy. Ofthe nine premenopausal patients
who were ER-negative, 2 (22%) responded to
oophorectomy. In the postmenopausal group 19 out
of 37 (51%) were ER-positive and of these 9 (47%)
7 respondedtotamoxifen. Outofthe 18postmenopausal
patients who were ER-negative, 3 (17%) responded
48 to tamoxifen.
FIGURE 2. Survival and concentration of ER. Percentage sur-
vival of 57 postmenopausal women undergoing simple mas-
tectomy in relation to concentration of ER: (o) ER +, 5-20
fmole/mg protein; (m) ER +, 21-100 fmole/mg protein.
100fmole/mgprotein(Fig. 2). Whenpostmenopausal
patients were analyzed according to tumor stage
(Fig. 3), the effect ofER status was only seen (and
was then markedly accentuated) in patients who
had lymph-node invasion at the time of mastecto-
my. These correlations were not observed in
premenopausal women where ER assays may be
distorted by endogenous estrogens.
ER Status and Response to Endocrine
Treatment
Table 1 shows the tumor response rates to
endocrine therapy in patients with recurrent breast
cancer in which the ER status of the primary
disease was known. Ofthe 57patients examined, 20
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Discussion
The present data clearly demonstrate that
postmenopausal women with ER-positive primary
breast tumors survive significantly longer than
those with ER-negative tumors. These data are
consistent with our previous findings in which the
length of the disease-free interval was found to
correlate with tumor ER status (3). The fact that
these relationships were established on the absence
ofadjuvant therapy suggests that the ER status of
the primary tumor is a measure of the natural
biology ofthe tumor. This concept is reinforced by
the finding that ER status is related to tumor
histological grade, well differentiated tumors rare-
ly lacking ER proteins (5). Interestingly, the ab-
sence of a relationship between tumor stage (by
lymph node status) and ER status makes these two
prognostic factors synergistic in the assessment of
prognosis. This synergism has been demonstrated
by our analysis ofthe effect in disease-free interval
(3) and survival (7) (Fig. 3).
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FIGURE 3. ER status, tumor staging, and survival. Percentage survival of 133 postmenopausal women
undergoing simple mastectomy in relation to ER status and lymph node staging: (e) ER +; (0) ER-.
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36Table 1. Response to endocrine therapy.a
ER + ER-
Premenopausal (oophorectomy) 4/11 (36%) 2/9 (23%)
Postmenopausal (tamoxifen) 9/19 (47%) 3/18 (17%)
aReceptor analysis was carried out on primary breast tumor
specimens.
In addition to the prognostic value of ER mea-
surements in primary breast tumor tissue, such
analysesalsoappeartobeofsomevalueinpredicting
the response of metastatic disease to tamoxifen
therapy in postmenopausal women. In patients
with ER-positive tumors the response rate of 47%
is "similar" to that observed when ER measure-
ments are carried out on metastatic deposits (8).
This effect was not however, observed in pre-
menopausal women undergoing oophorectomy where
only 36% (4/11) ofpatients with ER positive tumors
underwent an objective breast tumor remission, a
value only slightly higher than the overall response
rate (30%) forthis group. Conversely, the response
rates of 23% (2/9) and 17% (3/18) to oophorectomy
and tamoxifen therapyrespectively inpatients with
ER-negative primary tumors are higher than would
have been predicted on the basis of ER measure-
ments carried out on secondary breast tumortissue
(2). The numbers are at present, however, small.
Also the study is in its early stages and is dealing at
present with tumors of short disease-free interval.
A further period of observation is now required to
truly assess the value to the clinician of ER
measurements in primary breast cancer tissue in
relation to the subsequent response of the second-
ary disease to endocrine therapy. This is ofobvious
importance in that primary tumor tissue is always
accessible to the surgeon and is ofbetter quality for
the biochemist than is secondary tissue.
The authors wish to acknowledge the generous financial
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